Vensana Capital

Vensana Capital is a Minneapolis-based venture firm dedicated exclusively to medtech, with a practice spanning medical devices, diagnostics, and digital health. The firm was founded by partners who built their careers in medtech investing and operations, and it draws on Minnesota’s deep medical device ecosystem, which remains one of the most concentrated talent pools in the world for hardware-led healthcare innovation.

Vensana’s thesis is straightforward: back breakthrough innovations in medical devices, diagnostics, and digital health where capital and operational expertise can shorten the path to commercial scale. Portfolio companies including Apella, a surgical operations platform, and SpyGlass Pharma, a sustained-release ophthalmic drug delivery company, reflect the firm’s willingness to engage with both software-enabled clinical workflow and complex device-pharma combinations. AI is part of the thesis where it materially improves clinical workflow or diagnostic accuracy, but the firm remains anchored in physical-world clinical innovation rather than pure software bets.

The fund invests at Series A, Series B, and into growth rounds, writing checks in the $5M to $25M range. Geographic focus is primarily North America, though the firm will evaluate select international opportunities where clinical and regulatory pathways are clear. Founders should expect Vensana to lead or co-lead rounds, take board seats, and engage deeply on regulatory strategy, reimbursement design, and commercial scale-up.

The team is composed of partners with operating and investing experience at major medtech companies and prior medtech-specialist funds. This concentration of domain expertise produces a diligence process that is unusually substantive on clinical, regulatory, and reimbursement dimensions, which generalist investors typically delegate to outside consultants. Founders find that deep experience accelerates diligence on companies that fit and shortens the cycle to a clear yes or no.

Vensana’s working approach is high-conviction, lead-investor oriented, and operationally engaged. Founders describe partners who are present in the hard moments, including FDA correspondence, clinical trial design choices, and CMS coverage strategy, where most generalist VCs simply cannot contribute meaningfully. The firm typically takes board seats and prefers to back founders who welcome a hands-on partner rather than a passive capital provider. Reporting expectations are formal and aligned with regulated-product norms, including detailed clinical and regulatory updates alongside commercial metrics. Vensana will not be the right fit for founders building pure consumer health or generic SaaS plays, but for medtech founders, it is one of the most credible specialist firms operating today, with a network of strategic acquirers, hospital reference customers, and clinical opinion leaders that meaningfully accelerates portfolio companies. Capital efficiency and disciplined milestone planning are explicit expectations from the first conversation.